VRDN PEER ANALYSIS

Viridian Therapeutics Inc — metric-by-metric comparison with peers and the industry median

VRDNViridian Therapeutics Inc

🇺🇸 USA · NASDAQ · Healthcare · Biotechnology

Value it Duel

Overall Profile & Returns

· Biotechnology

Position Within Industry

0 = weak quartile, 100 = strong quartile

VRDNIndustry median

Scores normalize each metric against industry quartiles (p25–p75); direction is inverted for lower-is-better metrics.

Return Comparison

1-Year

Split-adjusted

Year-to-Date (YTD)

Key Metric Comparison

P/E

Lower is better

ROE

Higher is better

Net Margin

Higher is better

Revenue Growth

Higher is better

All Metrics

Valuation
Metric	VRDN	TLX	MSB	CSL	Ind. Median
P/E	—	—	—	30.02	17.81
P/B	3.05	6.56	—	2.24●	3.49
EV/EBITDA	—	123.31	—	10.37●	14.92
P/S	27.37	3.34	31.91	2.67●	10.89

Financial Health
Metric	VRDN	TLX	MSB	CSL	Ind. Median
Current Ratio	15.15●	1.43	—	2.57	5.90
Debt/Equity	8.0%●	112.3%	—	67.4%	10.9%
NetDebt/EBITDA	2.03●	13.13	—	2.22	1.15

Profitability
Metric	VRDN	TLX	MSB	CSL	Ind. Median
Net Margin	-508.5%	-0.9%	-115.3%	9.2%●	-125.7%
ROE	-58.1%	-1.8%	-11.3%	7.7%●	-47.5%
ROA	-49.7%	-0.7%	-8.6%	3.8%●	-35.8%
EBITDA Margin	-492.7%	3.0%	-76.6%	32.8%●	-105.8%

Growth + Dividend
Metric	VRDN	TLX	MSB	CSL	Ind. Median
Rev. Growth	23,382.8%●	56.3%	410.4%	4.8%	5.1%
NI Growth	—	—	—	-39.4%	12.1%
Div. Yield	—	—	0.0%	2.5%●	0.2%
Payout	—	—	0.0%	103.1%	0.0%

Valuation
Metric	VRDN	ZYME	RXRX	URGN	STOK	INVA	Ind. Median
P/E	—	—	—	—	—	3.67	17.81
P/B	3.05	11.57	2.05	-15.11●	5.18	1.38	3.49
EV/EBITDA	—	—	—	—	—	2.45	14.92
P/S	27.37	23.28	31.62	13.36	63.75	4.37●	10.89

Financial Health
Metric	VRDN	ZYME	RXRX	URGN	STOK	INVA	Ind. Median
Current Ratio	15.15	10.82	5.47	4.69	8.99	21.13●	5.90
Debt/Equity	8.0%	10.4%	7.1%	-158.6%●	0.9%	24.7%	10.9%
NetDebt/EBITDA	2.03	3.69	1.21	-0.48●	2.07	-0.44	1.15

Profitability
Metric	VRDN	ZYME	RXRX	URGN	STOK	INVA	Ind. Median
Net Margin	-508.5%	-126.3%	-844.5%	-94.8%	-529.2%	118.9%●	-125.7%
ROE	-58.1%	-42.0%	-57.2%	—	-45.6%	50.7%●	-47.5%
ROA	-49.7%	-22.7%	-42.3%	-53.2%	-39.9%	32.6%●	-35.8%
EBITDA Margin	-492.7%	-116.1%	-723.3%	-82.4%	-511.5%	150.9%●	-105.8%

Growth + Dividend
Metric	VRDN	ZYME	RXRX	URGN	STOK	INVA	Ind. Median
Rev. Growth	23,382.8%●	-13.0%	11.0%	52.9%	-83.2%	13.6%	5.1%
NI Growth	—	—	—	—	—	—	12.1%
Div. Yield	—	—	—	—	—	—	0.2%
Payout	—	—	—	—	—	—	0.0%

The green dot marks the best value in the group given the metric direction (higher/lower is better). All metrics use trailing-twelve-month (TTM) data.

Go deeper on VRDN

Run a DCF valuation

Full DCF model with editable assumptions

Start a head-to-head duel

Compare two stocks metric by metric

Filter in the stock screener

Build your own universe with 400+ metrics

Data on this page refreshes once per day. Price data as of Jul 6, 26. This content is for informational purposes only and is not investment advice.